Endologix (NSDQ:ELGX) last week announced that its Ovation Alto abdominal stent graft system has been used in its 1st 2 procedures to treat abdominal aortic anneurysms. The procedures were performed at New Zealand’s Auckland City Hospital by Dr. Andrew Holden and Dr. Andrew Hill, the Irvine, Calif.-based company said. “The 1st patients treated with the Ovation Alto […]
Endologix
Seno Medical grabs ex-CeloNova CFO Davis | Personnel Moves August 12, 2016
Seno Medical grabs ex-CeloNova CFO Davis Seno Medical Instuments said this week it tapped former CeloNova BioSciences chief financial officer Eric Davis to take over the CFO role at Seno Medical. Prior to his years at CeloNova, Davis operated as CFO and operating officer at Genesis Networks Enterprises. Seno Medical said that Davis has more than […]
Endologix releases Q2, updates on Nellix discussions with FDA
Endologix (NSDQ:ELGX) on Wednesday released 2nd quarter earnings and updated on its discussions with the FDA over its Nellix system for treating abdominal aortic aneurysms, saying the agency is requesting additional information and may need an Advisory Committee Panel before it can obtain approval. The company said that without a required panel, it is hopeful it […]
Endologix, TriVascular Technologies close $211m merger
Endologix (NSDQ:ELGX) and TriVascular Technologies (NSDQ:TRIV) said yesterday that they closed their $221 million merger, uniting 2 of the stent graft market’s smaller players. Both companies makes devices for treating abdominal aortic aneurysms; Irvine, Calif.-based Endologix makes 2 lines of stent grants, the Nellix and AFX devices, while Santa Rosa, Calif.-based TriVascular makes the Ovation stent graft. “The completion […]
Endologix, TriVascular clear U.S. regulatory hurdle in $211m merger
Endologix (NSDQ:ELGX) and TriVascular Technologies (NSDQ:TRIV) yesterday said that the waiting period set by U.S. anti-trust laws for their $211 million merger ended early, setting the stage for the deal to close during the 1st quarter next year. The companies said the U.S. Federal Trade Commission and Justice Dept. granted early termination of the waiting period under […]
Endologix, TriVascular Technologies ink $211m merger
Endologix (NSDQ:ELGX) and TriVascular Technologies (NSDQ:TRIV) yesterday said they plan to merge in a cash-and-stock deal worth $211 million. If consummated, the deal would unite 2 of the stent graft market’s smaller players. Both companies makes devices for treating abdominal aortic aneurysms; Irvine, Calif.-based Endologix makes 2 lines of stent grants, the Nellix and AFX devices, while […]
FDA clears Endologix’ AFX2 bifurcated stent graft
Endologix (NSDQ:ELGX) said it won FDA premarket approval for its AFX2 bifurcated endograft system for treating abdominal aortic aneurysms. The system is the newest-generation of AFX endovascular AAA product from the Irvine, Calif.-based company. The new version of the device reduces delivery and deployment procedure steps and can facilitate percutaneous endovascular aneurysm repair through a low-profile […]
Stryker eliminates international prez Subrahmanian’s role | Personnel Moves
Stryker (NYSE:SYK) said yesterday that it’s eliminating the role of international president held by Ramesh Subrahmanian as it reorganizes its overseas business. After Subrahmanian’s departure, effective Dec. 31, he’s slated to stay on until March 31, 2016, as an advisor, Stryker said in a regulatory filing. International sales were down across the board during Stryker’s […]
Endologix shares slide on Q2 misses
Endologix (NSDQ:ELGX) shares slid after Endologix released 2nd quarterly earnings showing slipping profits and earnings coupled with meager sales growth. Endologix reported losses of $13 million, a 19¢ loss per share, on sales of $39.5 million for the 3 months ended June 30. The numbers narrowly missed street sales estimates of $39.9 million. That amounts to a 43.3% […]